BioSpace News Archive

Total combined pro-forma revenue for 2020 was approximately $5.2 million Maintained strong balance sheet with $13.4 million cash as of December 31, 2020 Raised an additional $34.7 million of capital in the first quarter of 2021 Conference call to be held at 4:30 p.m. Eastern Time today

– LIFT-AD and ACT-AD studies evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling patients – – IND submissions planned for Parkinson’s disease dementia program in 1H 2021 and neuropsychiatric program by end of 2021 –

- Anticipating first patient for NL-201 Phase 1 Trial in 1H21 - - Cash and cash equivalents of $192.6 million expected to fund operations into 2023 - - Company to host Conference Call Today, March 25, 2021 at 1:30 p.m. Pacific / 4:30 p.m. Eastern -

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, LLC, an independent global pharmaceutical company.

Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, announced the nomination of Dominik Höchli, M.D., to the Company’s Board of Directors proposed for election at the 2021 Annual General Meeting on April 21, 2021.

Evotec SE reported financial results and corporate updates for the fiscal year ended 31 December 2020.

Medivir AB announced that the last patient with advanced liver cancer has been included in the first part of the phase Ib study with MIV-818.

Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies, announced today the presentation of new clinical data on LHF-535 at the International Conference on Antiviral Research

Bulgarian health and wellness brand Muno-Vax is trying to raise the bar when it comes to immunity health. The brand has made it its mission to “provide the highest quality and most effective immune supplements available on the market.”